Search research articles
Contact Us
Filters
Showing results (111-120 of 179) with videos related to
Page
of 18
Sort By:
Haematologica
|
June 24, 2021
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study
Andrew M Evens, Joseph M Connors, Anas Younes, et al.
Breast Cancer Research and Treatment
|
October 25, 2017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y Dirix, Istvan Takacs, Guy Jerusalem, et al.
NPJ Breast Cancer
|
May 21, 2021
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study
Linda T Vahdat, Peter Schmid, Andres Forero-Torres, et al.
Leukemia & Lymphoma
|
April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Mothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Leukemia & Lymphoma
|
October 3, 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study
Jeff P Sharman, Andres Forero-Torres, Luciano J Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 9, 2019
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Radhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, et al.
Leukemia & Lymphoma
|
September 6, 2007
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma
Jatin Shah, Wenquan Wang, V Douglas Harrough, et al.
Breast Cancer Research : BCR
|
February 20, 2020
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer
Christos Vaklavas, Brian S Roberts, Katherine E Varley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2015
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer
Denise A Yardley, Robert Weaver, Michelle E Melisko, et al.
Page
of 18
Search research articles
Search
Showing results (111-120 of 179) with videos related to
Sort By:
Page
of 18
Haematologica
|
June 24, 2021
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study
Andrew M Evens, Joseph M Connors, Anas Younes, et al.
Breast Cancer Research and Treatment
|
October 25, 2017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y Dirix, Istvan Takacs, Guy Jerusalem, et al.
NPJ Breast Cancer
|
May 21, 2021
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study
Linda T Vahdat, Peter Schmid, Andres Forero-Torres, et al.
Leukemia & Lymphoma
|
April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 31, 2019
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Mothaffar F Rimawi, Polly Niravath, Tao Wang, et al.
Leukemia & Lymphoma
|
October 3, 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study
Jeff P Sharman, Andres Forero-Torres, Luciano J Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 9, 2019
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Radhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, et al.
Leukemia & Lymphoma
|
September 6, 2007
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma
Jatin Shah, Wenquan Wang, V Douglas Harrough, et al.
Breast Cancer Research : BCR
|
February 20, 2020
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer
Christos Vaklavas, Brian S Roberts, Katherine E Varley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2015
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer
Denise A Yardley, Robert Weaver, Michelle E Melisko, et al.
Page
of 18